Citations (39)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Maria Teresa Mascellino, Barbara Porowska, Massimiliano De Angelis & Alessandra Oliva. (2017) Antibiotic susceptibility, heteroresistance, and updated treatment strategies in Helicobacter pylori infection. Drug Design, Development and Therapy 11, pages 2209-2220.
Read now
Read now
Laura A. Rhodes$suffix/text()$suffix/text(). (2017) Practical considerations for managing Helicobacter pylori in college health. Journal of American College Health 65:6, pages 361-362.
Read now
Read now
James Randolph Hillard & Suman Kashup. (2016) Managing Helicobacter pylori in college health, with special considerations for international students. Journal of American College Health 64:5, pages 404-408.
Read now
Read now
David Y. Graham & Maria Pina Dore. (2016) Helicobacter pylori therapy: a paradigm shift. Expert Review of Anti-infective Therapy 14:6, pages 577-585.
Read now
Read now
Articles from other publishers (35)
Yu Huang, Jinnan Chen, Zhaohui Ding, Xiao Liang & Hong Lu. (2022)
Susceptibility testing alone will not reliably achieve high
Helicobacter pylori
cure rates: A systematic review and meta‐analysis
. Journal of Gastroenterology and Hepatology 37:7, pages 1212-1221.
Crossref
Crossref
Maria Teresa Mascellino, Massimiliano De Angelis, Dania Al Ismail & Alessandra Oliva. 2021. Helicobacter pylori - From First Isolation to 2021. Helicobacter pylori - From First Isolation to 2021.
Luis Bujanda, Olga P. Nyssen, Dino Vaira, Ilaria M. Saracino, Giulia Fiorini, Frode Lerang, Sotirios Georgopoulos, Bojan Tepes, Frederic Heluwaert, Antonio Gasbarrini, Theodore Rokkas, Dmitry Bordin, Sinead Smith, Vincent Lamy, María Caldas, Elena Resina, Raquel Muñoz, Ángel Cosme, Ignasi Puig, Francis Megraud, Colm O’Morain & Javier P. Gisbert. (2021) Antibiotic Resistance Prevalence and Trends in Patients Infected with Helicobacter pylori in the Period 2013–2020: Results of the European Registry on H. pylori Management (Hp-EuReg). Antibiotics 10:9, pages 1058.
Crossref
Crossref
Emilia P. Yakovenko, Tatiana V. Strokova, Andrew V. Iakovenko, Alexander N. Ivanov, Irina P. Soluyanova & Nikolay N. Vasilyev. (2021) A prospective randomized comparative study of the efficacy and safety of a two-week bismuth-based quadrotherapy of <i> Helicobacter pylori </i> infection with the inclusion of the probiotic containing Bifidobacterium longum BB-46 and <i> Enterococcus faecium ENCfa-68 </i>. Terapevticheskii arkhiv 93:8, pages 916-922.
Crossref
Crossref
Qi Chen, Xiaohua Long, Yingjie Ji, Xiao Liang, Dongping Li, Hong Gao, Beili Xu, Ming Liu, Ying Chen, Yunwei Sun, Yan Zhao, Gang Xu, Yanyan Song, Lou Yu, Wei Zhang, Wenzhong Liu, David Y. Graham & Hong Lu. (2019)
Randomised controlled trial: susceptibility-guided therapy versus empiric bismuth quadruple therapy for first-line
Helicobacter pylori
treatment
. Alimentary Pharmacology & Therapeutics 49:11, pages 1385-1394.
Crossref
Crossref
Lou Yu, Laisheng Luo, Xiaohua Long, Xiao Liang, Yingjie Ji, Qi Chen, Yanyan Song, Xiaobo Li, David Y. Graham & Hong Lu. (2019)
Susceptibility-guided therapy for
Helicobacter pylori
infection treatment failures
. Therapeutic Advances in Gastroenterology 12, pages 175628481987492.
Crossref
Crossref
Hui Ye, Zong-ming Shi, Yao Chen, Jing Yu & Xue-zhi Zhang. (2018) Innovative Perspectives of Integrated Chinese Medicine on H. pylori. Chinese Journal of Integrative Medicine 24:11, pages 873-880.
Crossref
Crossref
Anne-Laure Rentien, Michaël Lévy, Christiane Copie-Bergman, Charlotte Gagniere, Jehan Dupuis, Yann Le Baleur, Karim Belhadj, Iradj Sobhani, Corinne Haioun, Jean-Charles Delchier & Aurelien Amiot. (2018) Long-term course of precancerous lesions arising in patients with gastric MALT lymphoma. Digestive and Liver Disease 50:2, pages 181-188.
Crossref
Crossref
Joonhwan KimKyungwon KimJun Soo LeeSu Young KimKyung Oh KimYoon Jae KimKwang an KwonDong Kyun ParkJun-Won Chung. (2018)
The Efficacy of Rebamipide or Ecabet Sodium Supplementation for
Helicobacter pylori
Eradication Therapy Compared with Quadruple (Concomitant) Regimen
. The Korean Journal of Gastroenterology 71:4, pages 204.
Crossref
Crossref
David Y Graham. (2017)
Illusions regarding
Helicobacter pylori
clinical trials and treatment guidelines
. Gut 66:12, pages 2043-2046.
Crossref
Crossref
I G Maev & A N Kazyulin. (2017) New opportunities for the prevention of gastric cancer. Terapevticheskii arkhiv 89:4, pages 101-109.
Crossref
Crossref
You-hua Wang, Zhi-fa Lv, Yao Zhong, Dong-sheng Liu, Shu-ping Chen & Yong Xie. (2017)
The internalization of
Helicobacter pylori
plays a role in the failure of
H. pylori
eradication
. Helicobacter 22:1, pages e12324.
Crossref
Crossref
Soichiro Sue, Nobumi Suzuki, Wataru Shibata, Tomohiko Sasaki, Hiroaki Yamada, Hiroaki Kaneko, Toshihide Tamura, Tomohiro Ishii, Masaaki Kondo & Shin Maeda. (2017)
First-Line
Helicobacter pylori
Eradication with Vonoprazan, Clarithromycin, and Metronidazole in Patients Allergic to Penicillin
. Gastroenterology Research and Practice 2017, pages 1-6.
Crossref
Crossref
Jyh-Ming Liou, Ming-Shiang Wu & Jaw-Town Lin. (2016)
Treatment of
Helicobacter pylori
infection: Where are we now?
. Journal of Gastroenterology and Hepatology 31:12, pages 1918-1926.
Crossref
Crossref
Jyh-Ming Liou, Chieh-Chang Chen, Chi-Yang Chang, Mei-Jyh Chen, Chien-Chuan Chen, Yu-Jen Fang, Ji-Yuh Lee, Tsung-Hua Yang, Jiing-Chyuan Luo, Jeng-Yih Wu, Tai-Cherng Liou, Wen-Hsiung Chang, Yao-Chun Hsu, Cheng-Hao Tseng, Chun-Chao Chang, Ming-Jong Bair, Tzeng-Ying Liu, Chun-Fu Hsieh, Feng-Yun Tsao, Chia-Tung Shun, Jaw-Town Lin, Yi-Chia Lee & Ming-Shiang Wu. (2016)
Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of
Helicobacter pylori
in the community and hospital populations: a randomised trial
. Gut 65:11, pages 1784-1792.
Crossref
Crossref
Jyh-Ming Liou, Yu-Jen Fang, Chieh-Chang Chen, Ming-Jong Bair, Chi-Yang Chang, Yi-Chia Lee, Mei-Jyh Chen, Chien-Chuan Chen, Cheng-Hao Tseng, Yao-Chun Hsu, Ji-Yuh Lee, Tsung-Hua Yang, Jiing-Chyuan Luo, Chun-Chao Chang, Chi-Yi Chen, Po-Yueh Chen, Chia-Tung Shun, Wen-Feng Hsu, Wen-Hao Hu, Yen-Nien Chen, Bor-Shyang Sheu, Jaw-Town Lin, Jeng-Yih Wu, Emad M El-Omar & Ming-Shiang Wu. (2016) Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. The Lancet 388:10058, pages 2355-2365.
Crossref
Crossref
Joon Sung Kim, Byung-Wook Kim, Su Jin Hong, Jin Il Kim, Ki-Nam Shim, Jie-Hyun Kim, Gwang Ho Baik, Sang Wook Kim, Hyun Joo Song & Ji Hyun Kim. (2016) Sequential Therapy versus Triple Therapy for the First Line Treatment of Helicobacter pylori in Korea: A Nationwide Randomized Trial. Gut and Liver 10:4, pages 556-561.
Crossref
Crossref
David Y. Graham & Loren Laine. (2016) The Toronto Helicobacter pylori Consensus in Context. Gastroenterology 151:1, pages 9-12.
Crossref
Crossref
Carlo A. Fallone, Naoki Chiba, Sander Veldhuyzen van Zanten, Lori Fischbach, Javier P. Gisbert, Richard H. Hunt, Nicola L. Jones, Craig Render, Grigorios I. Leontiadis, Paul Moayyedi & John K. Marshall. (2016) The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults. Gastroenterology 151:1, pages 51-69.e14.
Crossref
Crossref
Saman Alhooei, Hafez Tirgar Fakheri, Vahid Hosseini, Iradj Maleki, Tarang Taghvaei, Seyed Mohammad Valizadeh & Zohreh Bari. (2016) A Comparison between Hybrid and Concomitant Regimens for Helicobacter Pylori Eradication: A Randomized Clinical Trial. Middle East Journal of Digestive Diseases 8:3, pages 219-225.
Crossref
Crossref
Jyh-Ming Liou, Ming-Jong Bair, Chieh-Chang Chen, Yi-Chia Lee, Mei-Jyh Chen, Chien-Chuan Chen, Cheng-Hao Tseng, Yu-Jen Fang, Ji-Yuh Lee, Tsung-Hua Yang, Jiing-Chyuan Luo, Jeng-Yih Wu, Wen-Hsiung Chang, Chun-Chao Chang, Chi-Yi Chen, Po-Yueh Chen, Chia-Tung Shun, Wen-Feng Hsu, Hsu-Wei Hung, Jaw-Town Lin, Chi-Yang Chang & Ming-Shiang Wu. (2016) Levofloxacin Sequential Therapy vs Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori: A Randomized Trial. American Journal of Gastroenterology 111:3, pages 381-387.
Crossref
Crossref
David Y. Graham & Marjan Mohammadi. 2016. Helicobacter pylori. Helicobacter pylori
417
426
.
Kentaro Sugano, Jan Tack, Ernst J Kuipers, David Y Graham, Emad M El-Omar, Soichiro Miura, Ken Haruma, Masahiro Asaka, Naomi Uemura & Peter Malfertheiner. (2015)
Kyoto global consensus report on
Helicobacter pylori
gastritis
. Gut 64:9, pages 1353-1367.
Crossref
Crossref
David Y. Graham & Sun-Young Lee. (2015) How to Effectively Use Bismuth Quadruple Therapy. Gastroenterology Clinics of North America 44:3, pages 537-563.
Crossref
Crossref
Hassan Ali Metanat, Seyed Mohammad Valizadeh, Hafez Fakheri, Iradj Maleki, Tarang Taghvaei, Vahid Hosseini & Zohreh Bari. (2015)
Comparison Between 10- and 14-Day Hybrid Regimens for
Helicobacter pylori
Eradication: A Randomized Clinical Trial
. Helicobacter 20:4, pages 299-304.
Crossref
Crossref
H. Szajewska, A. Horvath & M. Kołodziej. (2015)
Systematic review with meta-analysis:
Saccharomyces boulardii
supplementation and eradication of
Helicobacter pylori
infection
. Alimentary Pharmacology & Therapeutics 41:12, pages 1237-1245.
Crossref
Crossref
D. Y. Graham & H. Lu. (2015)
Letter: bismuth, levofloxacin, amoxicillin,
PPI
quadruple therapy is not an effective first or second line regimen in the presence of levofloxacin resistance
. Alimentary Pharmacology & Therapeutics 41:11, pages 1220-1221.
Crossref
Crossref
David Y. Graham. (2015) Helicobacter pylori Update: Gastric Cancer, Reliable Therapy, and Possible Benefits. Gastroenterology 148:4, pages 719-731.e3.
Crossref
Crossref
Boo Gyoung KimJoon Sung KimByung-Wook KimJeong Seon JiHwang ChoiSung Min Park. (2015)
Annual Eradication Rates of
Helicobacter pylori
Infection over 9 Years in Incheon
. The Korean Journal of Helicobacter and Upper Gastrointestinal Research 15:2, pages 103.
Crossref
Crossref
David Y. Graham. (2015) Roadmap for elimination of gastric cancer in Korea. The Korean Journal of Internal Medicine 30:2, pages 133.
Crossref
Crossref
Xiaoqun Liu, Hui Wang, Zhifa Lv, Youhua Wang, Ben Wang, Yong Xie, Xiaojiang Zhou & Nonghua Lv. (2015)
Rescue Therapy with a Proton Pump Inhibitor Plus Amoxicillin and Rifabutin for
Helicobacter pylori
Infection: A Systematic Review and Meta-Analysis
. Gastroenterology Research and Practice 2015, pages 1-11.
Crossref
Crossref
Amin Talebi Bezmin Abadi. (2014) Helicobacter pylori: Emergence of a Superbug. Frontiers in Medicine 1.
Crossref
Crossref
Paul S. Hoffman, Alexandra M. Bruce, Igor Olekhnovich, Cirle A. Warren, Stacey L. Burgess, Raquel Hontecillas, Monica Viladomiu, Josep Bassaganya-Riera, Richard L. Guerrant & Timothy L. Macdonald. (2014) Preclinical Studies of Amixicile, a Systemic Therapeutic Developed for Treatment of Clostridium difficile Infections That Also Shows Efficacy against Helicobacter pylori. Antimicrobial Agents and Chemotherapy 58:8, pages 4703-4712.
Crossref
Crossref
Jeng-Yih Wu, Ping-I Hsu, Deng-Chyang Wu, David Y. Graham & Wen-Ming Wang. (2014)
Feasibility of Shortening 14-day Hybrid Therapy While Maintaining an Excellent
Helicobacter pylori
Eradication Rate
. Helicobacter 19:3, pages 207-213.
Crossref
Crossref
Halil Rakici, Teslime Ayaz, Remzi Adnan Akdogan & Recep Bedir. (2014) Comparison of Levofloxacin- and Moxifloxacin-Based Triple Therapies with Standard Treatment in Eradication of Helicobacter Pylori as First-Line Therapy. Digestion 90:4, pages 261-264.
Crossref
Crossref